Credit: Milestone Pharmaceuticals Cardamyst is supplied as a carton of 2 disposable nasal spray devices, each delivering 2 sprays containing a total of 70mg of etripamil. Cardamyst is expected to be ...
Etripamil is a calcium channel blocker designed to be administered intranasally to treat episodes of PSVT in an at-home setting. The Food and Drug Administration (FDA) has accepted for review the New ...
European decision on approval is expected by Q1 2027If approved, etripamil nasal spray is expected to offer patients a safe and effective ...
TipRanks on MSN
Milestone’s PSVT nasal spray MAA accepted by EMA
Milestone Pharmaceuticals ( ($MIST) ) has issued an announcement. On January 6, 2026, Milestone Pharmaceuticals announced that the European ...
MONTREAL and CHARLOTTE, N.C., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced plans to resubmit the New Drug Application (NDA) for etripamil to the ...
Self-administered intranasal etripamil was nearly twice as likely as placebo to terminate a paroxysmal supraventricular tachycardia (PSVT) episode within 30 minutes and reduced emergency department ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback